104 related articles for article (PubMed ID: 1445752)
41. Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer patients.
Unger C; Peukert M; Sindermann H; Hilgard P; Nagel G; Eibl H
Cancer Treat Rev; 1990 Sep; 17(2-3):243-6. PubMed ID: 2272039
[TBL] [Abstract][Full Text] [Related]
42. Synthesis of structural analogues of hexadecylphosphocholine and their antineoplastic, antimicrobial and amoebicidal activity.
Timko L; Fischer-Fodor E; Garajová M; Mrva M; Chereches G; Ondriska F; Bukovský M; Lukáč M; Karlovská J; Kubincová J; Devínsky F
Eur J Med Chem; 2015 Mar; 93():263-73. PubMed ID: 25698517
[TBL] [Abstract][Full Text] [Related]
43. Structure-activity relationships of alkylphosphocholine derivatives: antineoplastic action on brain tumor cell lines in vitro.
Jendrossek V; Hammersen K; Erdlenbruch B; Kugler W; Krügener R; Eibl H; Lakomek M
Cancer Chemother Pharmacol; 2002 Jul; 50(1):71-9. PubMed ID: 12111115
[TBL] [Abstract][Full Text] [Related]
44. Hexadecylphosphocholine causes rapid cell death in canine mammary tumour cells.
Duijsings D; Houweling M; Vaandrager AB; Mol JA; Teerds KJ
Eur J Pharmacol; 2004 Oct; 502(3):185-93. PubMed ID: 15476744
[TBL] [Abstract][Full Text] [Related]
45. Investigations on the cellular uptake of hexadecylphosphocholine.
Fleer EA; Berkovic D; Eibl H; Unger C
Lipids; 1993 Aug; 28(8):731-6. PubMed ID: 8377589
[TBL] [Abstract][Full Text] [Related]
46. Inhibition of phospholipase C delta by hexadecylphosphorylcholine and lysophospholipids with antitumor activity.
Pawelczyk T; Lowenstein JM
Biochem Pharmacol; 1993 Jan; 45(2):493-7. PubMed ID: 8435099
[TBL] [Abstract][Full Text] [Related]
47. Induction of tumor cell differentiation by alkylphosphocholines: a new approach for in vitro screening.
Maurer HR; Hilgard P
Prog Exp Tumor Res; 1992; 34():90-7. PubMed ID: 1438806
[No Abstract] [Full Text] [Related]
48. Synthesis and antiproliferative activity of alkylphosphocholines.
Agresta M; D'Arrigo P; Fasoli E; Losi D; Pedrocchi-Fantoni G; Riva S; Servi S; Tessaro D
Chem Phys Lipids; 2003 Dec; 126(2):201-10. PubMed ID: 14623454
[TBL] [Abstract][Full Text] [Related]
49. Chemically stable N-methyl-4-(alkylthio)cyclophosphamide derivatives as prodrugs of 4-hydroxycyclophosphamide.
Moon KY; Shirota FN; Baturay N; Kwon CH
J Med Chem; 1995 Mar; 38(5):848-51. PubMed ID: 7877150
[TBL] [Abstract][Full Text] [Related]
50. Sulfone metabolite of sulindac inhibits mammary carcinogenesis.
Thompson HJ; Jiang C; Lu J; Mehta RG; Piazza GA; Paranka NS; Pamukcu R; Ahnen DJ
Cancer Res; 1997 Jan; 57(2):267-71. PubMed ID: 9000566
[TBL] [Abstract][Full Text] [Related]
51. Induction of resistance to hexadecylphosphocholine in the highly sensitive human epidermoid tumour cell line KB.
Fleer EA; Berkovic D; Grunwald U; Hiddemann W
Eur J Cancer; 1996 Mar; 32A(3):506-11. PubMed ID: 8814699
[TBL] [Abstract][Full Text] [Related]
52. Effects of hexadecylphosphocholine on fatty acid metabolism: relation to cytotoxicity.
Goppelt-Struebe M; Winter I
Cancer Chemother Pharmacol; 1995; 35(6):519-26. PubMed ID: 7882461
[TBL] [Abstract][Full Text] [Related]
53. Alkylphosphocholines: Effects on human leukemic cell lines and normal bone marrow cells.
Konstantinov SM; Topashka-Ancheva M; Benner A; Berger MR
Int J Cancer; 1998 Aug; 77(5):778-86. PubMed ID: 9688313
[TBL] [Abstract][Full Text] [Related]
54. Tat peptide and hexadecylphosphocholine introduction into pegylated liposomal doxorubicin: An in vitro and in vivo study on drug cellular delivery, release, biodistribution and antitumor activity.
Teymouri M; Badiee A; Golmohammadzadeh S; Sadri K; Akhtari J; Mellat M; Nikpoor AR; Jaafari MR
Int J Pharm; 2016 Sep; 511(1):236-244. PubMed ID: 27363937
[TBL] [Abstract][Full Text] [Related]
55. Molecular and cellular effects of hexadecylphosphocholine (Miltefosine) in human myeloid leukaemic cell lines.
Beckers T; Voegeli R; Hilgard P
Eur J Cancer; 1994; 30A(14):2143-50. PubMed ID: 7857715
[TBL] [Abstract][Full Text] [Related]
56. Cytotoxic effects of alkylphosphocholines or alkylphosphocholine-liposomes and macrophages on tumor cells.
Zeisig R; Jungmann S; Fichtner I; Daemen T; Arndt D
Anticancer Res; 1994; 14(5A):1785-9. PubMed ID: 7847811
[TBL] [Abstract][Full Text] [Related]
57. Experimental therapeutic studies with miltefosine in rats and mice.
Hilgard P; Stekar J; Voegeli R; Harleman JH
Prog Exp Tumor Res; 1992; 34():116-30. PubMed ID: 1438794
[No Abstract] [Full Text] [Related]
58. Effects of hexadecylphosphocholine on cellular function.
Berkovic D; Fleer EA; Eibl H; Unger C
Prog Exp Tumor Res; 1992; 34():59-68. PubMed ID: 1438803
[No Abstract] [Full Text] [Related]
59. Comparison of the tissue distribution of hexadecylphosphocholine and erucylphosphocholine.
Reitz RC; Kötting J; Unger C; Eibl H
Prog Exp Tumor Res; 1992; 34():143-52. PubMed ID: 1438797
[No Abstract] [Full Text] [Related]
60. Antiinvasive activity of hexadecylphosphocholine in vitro.
Schallier DC; Bruyneel EA; Storme GA; Hilgard P; Mareel MM
Anticancer Res; 1991; 11(3):1285-92. PubMed ID: 1888162
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
